Medicinal uses of mu-opioid receptor agonists

Details Medicinal uses of mu-opioid receptor agonists Medicinal uses of mu-opioid receptor agonists

2006-06-29

2010-06-08

Bunner, Bridget E (Department: 1649)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S009100, C514S017400

Reexamination Certificate

active

07732398

ABSTRACT:
The present invention provides methods for stimulating mu-opioid receptors with agonist peptides in a mammal in need thereof. The methods comprise administering to the mammal an effective amount of a selective mu-opioid receptor agonist peptide that comprises at least two α-amino acid residues. At least one of the amino acid residues has a positive charge. The amino acid residue in the first position is a tyrosine or tyrosine derivative. The amino acid in the second position is a D-α-amino acid. The present invention also provides methods of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the peptides.

REFERENCES:
patent: 5312899 (1994-05-01), Schiller
patent: 5602100 (1997-02-01), Brown et al.
patent: 5993848 (1999-11-01), Suzuki et al.
patent: 6703483 (2004-03-01), Schiller
patent: 6900178 (2005-05-01), Oeltgen et al.
patent: 2361364 (0000-09-01), None
patent: WO95/22557 (1995-08-01), None
patent: WO 9522557 (1995-08-01), None
patent: WO-97/07130 (1997-02-01), None
patent: WO 00/55189 (2000-09-01), None
Wells, 1990, Biochemistry 29:8509-8517.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Zhao et al. J. Pharmacol Exp Ther. 2002; 302: 188-196.
Lishmanov et al. Life Sciences; 65: PL 13-17, print copy available Jun. 2, 1999.
Guerrini et al. Euro J Pharmacol. 1996; 302: 37-42.
Zschiedrich et al., Klin Wochenschr. 1983, 1: 661-7.
Kanto, Int J Clin Pharmacol Ther Toxicol. 1987, 25: 166-74.
Demas et al., Br J Anaesth. 1986; 58: 1357-1564.
Shroff et al., J Clin Anesthesia. 1997; 9: 415-419.
Schiller, et al., “Opioid peptide analogs with novel activity profiles as potential therapeutic agents for use in analgesia”, Peptide Science-Present and Future, Proc. Int. Pept. Symp., 1st, Y. Shimonishi (ed), 1999, pp. 665-669.
Schiller, et al., “Opioid Peptide Analogs With Novel Activity Profiles as Potential Therapeutic Agents For Use in Analgesia”, First International Peptide Symposium, Program & Abstracts, Nov. 30-Dec. 5, 1997, Kyoto, Japan, 0-36, p. 77.
Zhao, et al., “Cell-permeable Peptide Antioxidants Targeted to Inner Mitochondrial Membrane inhibit Mitochondrial Swelling, Oxidative Cell Death, and Reperfusion Injury”, J. Biol. Chem., Aug. 2004, vol. 279, No. 33, pp. 34682-34690.
Clapp III, et al. “Cardiovascular and Metabolic Responses to Two Receptor-Selective Opioid Agonists in Pregnant Sheep”, Am. J. Obstet. Gynecol., vol. 178, No. 2 (Feb. 1998) pp. 397-401.
Holsey, et al. “Cardiovascular Effects of a μ-Selective Opioid Agonist (Tyrosine-D-Arginine-Phenylalanine-Lysine-NH2) in Fetal Sheep: Sites and Mechanisms of Action”, Am. J. Obstet. Gynecol., vol. 180, No. 5 (May 1999) pp. 1127-1130.
Kett, et al. “Baroreflex-Mediated Bradycardia but Not Tachycardia is Blunted Peripherally by Intravenous μ-opioid Agonists”, Am. J. Obstet. Gynecol., vol. 178, No. 5 (May 1998) pp. 950-955.
Neilan, et al. “Pharmacological Characterization of the Dermorphin Analog [Dmt1]DALDA, a Highly Potent and Selective μ-Opioid Peptide”, European Journal of Pharmacology, vol. 419, Issue 1 (2001) 15-23.
Omoniyi, et al. “A Peripheral Site of Action for the Attenuation of Baroreflex-Mediated Bradycardia by Intravenous μ-Opioid Agonists”, Journal of Cardiovascular Pharmacology™, vol. 35, No. 2 (2000) pp. 269-274.
Schiller, et al. “Dermorphin Analogucs Carrying an Increased Positive Net Charge in Their “Message” Domain Display Extremely High μ Opioid Receptor Selectivity”, Journal of Medicinal Chemistry, vol. 32, No. 3 (1989) pp. 698-703.
Schiller, et al. “Synthesis and In Vitro Opioid Activity Profiles of DALDA Analogues”, European Journal of Medicinal Chemistry, vol. 35, Issue 10 (Oct. 2000) pp. 895-901.
Shimoyama, et al. “Antinociceptive and Respiratory Effects of Intrathecal H-Tyr-D-Arg-Phe-Lys-NH2(DALDA) and [Dmt1] DALDA”, The Journal of Pharmacology and Experimental Therapeutics, vol. 297, No. 1 (Apr. 2001) pp. 364-371.
Szeto, et al. “In Vivo Disposition of Dermorphin Analog (DALDA) in Nonpregnant and Pregnant Sheep”, The Journal of Pharmacology and Experimental Therapeutics, vol. 284, No. 1 (1998) pp. 61-65.
Szeto et al. “Respiratory Depression After Intravenous Administration of δ-Selective Opioid Peptide Analogs”, Peptides, vol. 20 (1999) pp. 101-105.
Szeto, et al. “Mu-Opioid Receptor Densensitization and Resensitization In Vivo”, International Narcotics Research Conference, Poster Abstracts, Monday (1999) Mon19, p. 5.
Szeto, et al. “In Vivo Pharmacokinetics of Selective μ-Opioid Peptide Agonists”, The Journal of Pharmacology and Experimental Therapeutics, vol. 298, No. 1 (Jul. 2001) pp. 57-61.
Wu, et al. “Myocardial Protective Effect of Mu Opioid Agonists”, International Narcotics Research Conference, Poster Abstracts, Sunday (1999) Sun59, p. 15.
Zadina et al., “A Potent and Selective endogenous Agonist for the μ-Opiate Receptor”, Nature, vol. 386, pp. 499-502(1997).
Spetea, et al., “Interaction of Agonist Peptide [3H] Try-D-Ala-Phe-Phe-NH2 with μ-Opioid Receptor in Rat Brain and CHO-μ/1 Cell Line”, Peptides, vol. 19, No. 6, pp. 1091-1098 (1998).
Dooley et al., “Selective Ligands for the μ,δ, and κ Opioid Receptors Identified from a Single Mixture Based Tetrapeptide Positional Scanning Combinatorial Library”, Journal of Biological Chemistry, vol. 273, No. 30, pp. 18848-18856 (1998).
Schiller et al., “Opioid Peptide Analogs with Novel Activity Profiles as Potential Therapeutic Agents for Use in Analgesia”, Pept. Sci, Present Future, Proc. Int. Pept. Symp., 1st, pp. 665-669 (1999).
Bork, “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle”, 2000, Genome Research 10:398-400.
Skolnick et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era”, 2000, Trends in Biotech. 18(1):34-39.
Doerks et al., “Protein annotation: detective work for function prediction”, 1998, Trends in Genetics 14:248-250.
Smith et al., “The challenges of genome sequence annotation or ‘The devil is in the details’”, 1997, Nature Biotechnology 15: 1222-1223.
Brenner, “Errors in genome annotation”, 1999, Trends in Genetics 15:132-133.
Bork et al., “Go hunting in sequence databases but watch out for the traps”, 1996, Trends in Genetics 12:425-427.
Lasukova et al., “Activation of mu-opioid receptors and cardiomyocyte resistance to free radical damage”, Patol Fiziol Eksp Ter. 2001 2: Abstract Only; article in Russian.
Song et al., “A potent opiate agonist protects against myocardial stunning during myocardial ischemia and reperfusion in rats”, Coronary Artery Disease, 2005; 16: 407-410.
Herve et al., “On the Immunogenic Properties of Retro-Inverso Peptides. Total Retro-Inversion of T-Cell Epitopes Causes a Loss of Binding to MHC II Molecules”, Molecular Immunology, vol. 34, No. 2, pp. 157-163 (1997).
Communication pursuant to Article 94(3) EPC in European Patent Application No. 01955855.0, dated Jul. 27, 2009.
Canadian Office Action, dated Sep. 10, 2009, in Canadian Patent Application No. 2,416,475.

Affiliated with

Also associated with

Rating

Medicinal uses of mu-opioid receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medicinal uses of mu-opioid receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicinal uses of mu-opioid receptor agonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4249123